Actionnariat et activité des initiés pour Evolus, Inc. (EOLS): transactions des initiés, déclarations de trading du Sénat et de la Chambre américaine et actions en circulation. Suivez comment dirigeants et politiciens négocient le titre.
Prix
| Prix | $7.99 |
| Capitalisation | $526M |
| Bourse | NASDAQ |
| Pays | US |
Transactions d'Initiés Récentes
| Date | Initié | Type | Actions | Valeur |
|---|---|---|---|---|
| 2026-09-02 | MOATAZEDI DAVID | S-Sale | 105,108 | $950K |
| 2026-03-20 | Avelar Rui | S-Sale | 3,119 | $15K |
| 2026-03-20 | MOATAZEDI DAVID | S-Sale | 13,669 | $65K |
| 2026-03-16 | MOATAZEDI DAVID | M-Exempt | 67,489 | |
| 2026-03-17 | MOATAZEDI DAVID | S-Sale | 116,720 | $571K |
| 2026-03-16 | MOATAZEDI DAVID | M-Exempt | 67,489 | |
| 2026-03-16 | Avelar Rui | M-Exempt | 8,804 | |
| 2026-03-17 | Avelar Rui | S-Sale | 29,996 | $147K |
| 2026-03-16 | Avelar Rui | M-Exempt | 8,804 | |
| 2026-02-17 | Parschauer Karah Herdman | A-Award | 45,559 |
Bilan (10 ans)
| Année | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Trésorerie | 0 | 0 | $93.2M | $109.9M | $102.6M | $146.3M | $53.9M | $62.8M | $87.0M | $53.8M |
| Placements à Court Terme | 0 | 0 | 0 | $19.9M | $5.0M | 0 | 0 | 0 | 0 | 0 |
| Créances | 0 | $72.6M | 0 | $10.7M | $9.7M | $14.7M | $22.4M | $30.5M | $47.7M | $54.7M |
| Stocks | 0 | 0 | 0 | $6.4M | $3.4M | $1.8M | $18.9M | $11.0M | $12.2M | $27.0M |
| Actifs Courants | $211000 | $72.8M | $94.3M | $152.2M | $127.6M | $178.8M | $100.8M | $112.4M | $151.3M | $142.9M |
| Immobilisations Corporelles | 0 | 0 | 0 | $5.0M | $4.7M | $4.1M | $4.6M | $7.8M | $10.4M | $12.5M |
| Goodwill | $21.2M | $21.2M | $21.2M | $21.2M | $21.2M | $21.2M | $21.2M | $21.2M | $21.2M | $21.2M |
| Actifs Incorporels | $56.1M | $56.1M | $56.1M | $59.6M | $55.3M | $50.6M | $48.6M | $47.1M | $48.8M | $48.0M |
| Actifs Totaux | $77.5M | $152.2M | $171.8M | $240.4M | $209.1M | $257.5M | $178.0M | $189.0M | $232.6M | $225.9M |
| Dettes Fournisseurs | $2.9M | $445000 | $1.6M | $5.8M | $9.6M | $6.1M | $8.9M | $4.3M | $9.2M | $23.4M |
| Dette à Court Terme | $59.8M | $211.3M | 0 | 0 | $93.5M | 0 | 0 | 0 | 0 | 0 |
| Passifs Courants | $63.3M | $212.7M | $5.3M | $24.4M | $180.2M | $57.7M | $46.5M | $48.3M | $63.0M | $75.3M |
| Dette à Long Terme | 0 | 0 | $16.9M | $91.5M | $40.5M | $71.2M | $71.9M | $120.4M | $121.5M | $146.1M |
| Passifs Totaux | $84.6M | $227.8M | $87.5M | $161.0M | $282.0M | $175.6M | $159.5M | $209.7M | $227.0M | $249.0M |
| Réserves | -$66.8M | -$75.5M | -$123.0M | -$213.1M | -$376.1M | -$422.9M | -$497.3M | -$559.0M | -$609.4M | -$661.0M |
| Capitaux Propres | -$7.1M | -$75.5M | -$123.0M | $79.5M | -$73.0M | $81.9M | $18.5M | -$20.7M | $5.5M | -$23.1M |
| Dette Totale | $59.8M | $211.3M | $16.9M | $96.5M | $138.3M | $74.7M | $74.4M | $126.5M | $130.0M | $155.0M |
| Dette Nette | $59.8M | $211.3M | -$76.3M | -$33.3M | $30.8M | -$71.5M | $20.5M | $63.7M | $43.0M | $101.2M |
| Fonds de Roulement | -$63.1M | -$139.9M | $89.1M | $127.8M | -$52.6M | $121.1M | $54.3M | $64.1M | $88.4M | $67.6M |
Santé financière
| Dette / Capitaux propres | -5.33 |
| Ratio de liquidité | 1.70 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -1.94 |
Rentabilité
| Rentabilité des capitaux propres | 123.11% |
| Rentabilité du capital investi | -15.27% |
| Rentabilité des actifs | -13.84% |
| Marge brute | 66.25% |
| Marge opérationnelle | -7.33% |
| Marge nette | -10.85% |
Entreprises liées: AUTL · CBLL · EHAB · KIDS · KMDA · NGNE · QSI
Explorer le secteur: Healthcare · Drug Manufacturers - Specialty & Generic
Plus de sections de EOLS: Vue d'ensemble · Financiers · Valorisation · Statistiques · Estimations · Technique · Actualités · Événements
Découvrir plus: Radar — signaux d'actions sous-évaluées · Académie d'Investissement — apprenez à analyser les actions